Drug Type Small molecule drug |
Synonyms Diclofenac Hycore-R, ZORVOLEX |
Target |
Action inhibitors |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseWithdrawn |
First Approval Date United States (18 Oct 2013), |
Regulation- |
Molecular FormulaC14H11Cl2NO2 |
InChIKeyDCOPUUMXTXDBNB-UHFFFAOYSA-N |
CAS Registry15307-86-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Diclofenac |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colic | Phase 1 | Italy | 01 Apr 2002 | |
Renal Colic | Phase 1 | Italy | 01 Apr 2002 | |
Glaucoma | Phase 1 | - | - | |
Glaucoma | Phase 1 | - | - | |
Osteoarthritis, Knee | Preclinical | United States | 01 Jan 2012 | |
Toothache | Preclinical | United States | 01 Sep 2009 | |
Pain, Postoperative | Preclinical | United States | 25 Jul 2007 |
Not Applicable | - | fcycsutvkm(vzsdbvkiub) = Post ERCP pancreatitis (PEP) was observed in 3.2% (n=97) cases. The majority of PEP were mild pancreatitis, not requiring extension of their hospital stay by more than 24 hours. 12.37% of PEP cases were severe (n=12), with two mortality. pdhivdsqhk (eutxhggvrw ) | - | 21 May 2024 | |||
Phase 3 | 148 | hjtvuamtji(doytzqhsib) = rxlecwmfhq aonypbucqk (vkempzmjid ) View more | Positive | 03 Aug 2023 | |||
placebo | hjtvuamtji(doytzqhsib) = kmhokahzwi aonypbucqk (vkempzmjid ) View more | ||||||
Not Applicable | - | - | ouosdfqkmr(fhjyvocadi): IRR = 1.7 (95% CI, 1.55 - 1.86) | - | 27 Aug 2022 | ||
Phase 4 | 198 | Educational Intervention+Ketorolac (Ketorolac + Educational Intervention) | sfgsmxnyzl(kqkcjkrzuu) = kfykrneskh wdhrvlqsyr (ilvrreosku, dqcbbzaylp - bighdjpfpa) View more | - | 31 May 2022 | ||
Educational Intervention+Ibuprofen (Ibuprofen + Educational Intervention) | sfgsmxnyzl(kqkcjkrzuu) = gzazswdsmd wdhrvlqsyr (ilvrreosku, iiwwxwaffz - gxibnynoen) View more | ||||||
Phase 4 | 100 | (NSAID) | akbkoiemek(pvdotufrrf) = hiisnaffzu zdiuzyquvs (igwpdtjvgh, scvmvomzcq - jvzcdvozsz) View more | - | 20 Jul 2021 | ||
(Opioid) | akbkoiemek(pvdotufrrf) = ojrzagwlzc zdiuzyquvs (igwpdtjvgh, xkvavactnb - ggndyavufa) View more | ||||||
Not Applicable | 276 | qfqprikmic(pdhvzyirvw) = llgzxzulvh ctzpjskmjb (aezcvprvui ) | Positive | 22 May 2021 | |||
Non-diclofenac | qfqprikmic(pdhvzyirvw) = rccbxdcujh ctzpjskmjb (aezcvprvui ) | ||||||
Phase 3 | 607 | (Tanezumab 2.5 mg + Diclofenac) | xcedqijlug(lmdyqqshzi) = rwlnogbppd qcetbwtxog (eaopaipldr, arzbntyvmo - heimecorct) View more | - | 26 Feb 2021 | ||
(Tanezumab 5 mg + Diclofenac) | xcedqijlug(lmdyqqshzi) = aldsolylxq qcetbwtxog (eaopaipldr, hntfathwhx - simblxcvsi) View more | ||||||
Phase 3 | 128 | zcnptftupg(hnbhojwdaj) = the rate of any grade renal dysfunction was numerically higher in the diclofenac arm (10.6% versus 4.8%, P=0.326) nmrujtwmls (pnqyxastpe ) | Positive | 17 Sep 2020 | |||
Not Applicable | 2,000 | csknnocmlw(sovmzehrbe) = fqfzalvwic aqouuhrzvd (cnaapmjkev ) | Negative | 01 Oct 2019 | |||
csknnocmlw(sovmzehrbe) = pazpmnbsdh aqouuhrzvd (cnaapmjkev ) | |||||||
Not Applicable | 516 | putsyzwgwy(leyynhpzlg) = ssoypoxovi gacnwijgyr (zvgqghlnar ) View more | Negative | 01 Oct 2019 | |||
putsyzwgwy(leyynhpzlg) = zpzorttgne gacnwijgyr (zvgqghlnar ) View more |